Form 4: Insider Trading: Director Acquires PSTV Stock Options

Ronald Asbury, a Director at PLUS THERAPEUTICS, INC., reported transactions involving the acquisition of restricted stock units and stock options.

Summary

• Ronald Asbury, a Director of PLUS THERAPEUTICS, INC. (PSTV), reported the acquisition of 3,686 Restricted Stock Units (RSUs) and two sets of stock options on May 14, 2026.
• The RSUs vest ratably over four quarters, with the first 1/4 vesting on July 1, 2026.
• One set of stock options, with an exercise price of $5.76, includes 3,686 shares and vests monthly over 12 months, with full vesting by the Issuer's 2027 Annual Stockholder Meeting.
• Another set of stock options, also with an exercise price of $5.76, includes 1,600 shares and vests monthly over 24 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports standard insider equity awards with typical vesting schedules, indicating ongoing compensation and incentive alignment rather than a significant strategic event.

Positives

• Director Ronald Asbury has acquired equity in the company through RSUs and stock options, indicating a commitment to the company's future.
• The vesting schedules for the RSUs and stock options are spread over time, aligning the director's incentives with long-term company performance.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term outlook for the company, with incentives tied to continued service and performance through 2027.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of equity awards by directors, are common in the biotechnology and pharmaceutical sectors as a means to attract and retain key talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director can be viewed positively as it aligns management's interests with those of shareholders.
• Employees: The vesting schedules for RSUs and options may influence employee retention and motivation.
• Management: The awards are part of the compensation structure for the director.

Next Steps

• Vesting of Restricted Stock Units commencing July 1, 2026.
• Monthly vesting of stock options over 12 and 24 months.
• Full vesting of certain stock options by the Issuer's 2027 Annual Stockholder Meeting.

Key Dates

Keywords

Insider Trading, Form 4, PLUS THERAPEUTICS, PSTV, Director, Stock Options, Restricted Stock Units, Equity Award, SEC Filing